Article
Public, Environmental & Occupational Health
Xiaoyan Liu, Yitian Lang, Yahui Liao, Yizhun Zhu
Summary: The study assessed the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health sector. While adding atezolizumab to nab-paclitaxel showed significant improvement in survival time for PD-L1-positive group, it was not a cost-effective strategy compared to nab-paclitaxel monotherapy for Chinese patients with advanced or metastatic TNBC in the context of current economic situation in China.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Oncology
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Summary: The ANASTASE study retrospectively analyzed data from PD-L1-positive mTNBC patients treated with atezolizumab plus nab-paclitaxel and found similar results in terms of PFS and ORR as reported in the IMpassion130 study, with no unexpected adverse events.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber, Ryan Sun, Senthil Damodaran, Rashmi K. Murthy, David Ramirez, Meghan Karuturi, Rachel M. Layman, Nuhad Ibrahim, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Elizabeth Ravenberg, Alyson Clayborn, Qing Qing Ding, W. Fraser Symmans, Sabitha Prabhakaran, Alastair M. Thompson, Vicente Valero, Debu Tripathy, Lei Huo, Stacy L. Moulder, Jennifer K. Litton
Summary: Neoadjuvant anti-PD-(L)1 therapy improves the pCR rate in unselected TNBC, but optimizing the risk-benefit ratio for these agents is important. This phase II study demonstrated a promising activity of atezolizumab and nab-paclitaxel as the second phase of NAT in AC-resistant TNBC, suggesting a response-adapted approach to neoadjuvant immunotherapy for further evaluation.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
L. A. Emens, S. Adams, C. H. Barrios, V Dieras, H. Iwata, S. Loi, H. S. Rugo, A. Schneeweiss, E. P. Winer, S. Patel, V Henschel, A. Swat, M. Kaul, L. Molinero, S. Patel, S. Y. Chui, P. Schmid
Summary: The study showed that although A + nP for first-line treatment of triple-negative breast cancer did not significantly improve overall survival in the overall population, clinically meaningful benefits were observed in patients with PD-L1 expression on tumor infiltrating immune cells. The combination therapy remained safe and tolerable with longer follow-up.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurelie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jerome Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini
Summary: The AtezoTRIBE phase II study shows that adding atezolizumab to first-line FOLFOXIRI plus bevacizumab can prolong progression-free survival in patients with metastatic colorectal cancer (mCRC), especially for those with proficient mismatch repair (pMMR). DetermaIO, a 27-gene expression signature, is able to predict the benefits of immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, the predictive impact of DetermaIO in mCRC was investigated.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Anna R. Schreiber, Jodi Kagihara, Megan Eguchi, Peter Kabos, Christine M. Fisher, Elisabeth Meyer, Elizabeth Molina, Lavanya Kondapalli, Cathy J. Bradley, Jennifer R. Diamond
Summary: The study evaluated the effect of adjuvant anthracycline + taxane (ATAX) versus taxane-based (TAX) chemotherapy on cancer-specific (CSS) and overall survival (OS) in older patients with node-negative TNBC. The results showed that while adjuvant chemotherapy improved clinical outcomes, the administration of ATAX compared to TAX was associated with inferior 3-year OS and CSS in this patient population.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Oncology
Dorota Kwapisz
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options, but it shows higher immunogenicity, tumor-infiltrating lymphocytes (TILs) enrichment, and programmed cell death ligand 1 (PD-L1) expression which make it more suitable for immune checkpoint blockade therapy. Patients with PD-L1-positive TNBC subgroup may benefit the most from immune checkpoint inhibitor (ICI) treatment, and ICI given as first-line treatment in advanced TNBC shows better results than in later lines of treatment. Exciting results have been seen with pembrolizumab in early-stage TNBC, indicating potential approval in (neo)adjuvant settings in the near future.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina, Peter Kabos, Marie Wood, Anthony Elias, Lavanya Kondapalli, Cathy J. Bradley, Jennifer R. Diamond
Summary: This study investigated the impact of anthracycline plus taxane (ATAX) regimens and non-anthracycline-containing, taxane-based (TAX) regimens on the survival rate of older women with triple-negative breast cancer (TNBC). The results showed that adjuvant chemotherapy improved cancer-specific survival (CSS) and overall survival (OS) in TNBC patients. There was a trend towards better outcomes with ATAX for patients with more than 4 positive lymph nodes.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Jiayu Wang, Tao Sun, Quchang Ouyang, Yiqun Han, Binghe Xu
Summary: This study investigated the safety and preliminary efficacy of TQB2450, an anti-PD-L1 antibody, combined with anlotinib, a multi-kinase inhibitor, in advanced TNBC. The results showed that the combination therapy of TQB2450 and anlotinib as a chemotherapy-free treatment demonstrated promising efficacy with a manageable safety profile for previously treated advanced TNBC patients.
Article
Oncology
Eve Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori Goldstein, Debu Tripathy, Ursa A. Brown-Glaberman, Thu-Tam Huynh, Christopher S. Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobagyi
Summary: PARP inhibitors are effective in germline BRCA1/2-mutated metastatic breast cancer. This study demonstrates that adding veliparib to cisplatin improves progression-free survival in patients with BRCA-like metastatic triple-negative breast cancer.
Article
Oncology
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Summary: Chemoimmunotherapy with anti-PD-1/L1 and cytotoxic chemotherapy is a promising treatment for triple-negative breast cancer, but further research is needed to determine the optimal chemotherapy regimen and biomarkers for patient selection. This study investigated the safety and efficacy of pembrolizumab in combination with paclitaxel or capecitabine, and found that both regimens were safe and clinically active.
Article
Multidisciplinary Sciences
Alexandre de Moura, Perrine Vuagnat, Benjamin Renouf, Jean-Yves Pierga, Delphine Loirat, Pauline Vaflard, Charline Lafayolle de la Bruyere, Natacha Chaumard-Billotey, Nawale Hajjaji, Sylvain Ladoire, Sandrine Dabakuyo, Anne Patsouris, Jean Sebastien Frenel, Vincent Nicolai, Marie Alexandre, Nadine Dohollou, Julien Grenier, Heloise Bourien, Francois-Clement Bidard
Summary: According to a retrospective multicentric analysis conducted in France, the combination of atezolizumab and paclitaxel showed limited efficacy in PD-L1-positive advanced triple negative breast cancer, especially in patients receiving corticosteroids before treatment initiation.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodriguez-Abreu, Denis Moro-Sibilot, Christian A. Thomas, Fabrice Barlesi, Gene Finley, Shengchun Kong, Anthony Lee, Shelley Coleman, Wei Zou, Mark McCleland, Geetha Shankar, Martin Reck
Summary: The final analysis of IMpower150 study showed a numerical OS improvement with ACP compared to BCP in metastatic nonsquamous NSCLC patients, while ABCP demonstrated continued OS improvement in all patients.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Imteyaz Ahmad Khan, Sucharita Pilli, A. Surendranath, Ritika Rampal, Sudhir Kumar Chauhan, Veena Tiwari, Venigalla Pratap Mouli, Saurabh Kedia, Baibaswata Nayak, Prasenjit Das, Govind K. Makharia, Vineet Ahuja
Article
Multidisciplinary Sciences
Richa Rai, Sudhir Kumar Chauhan, Vikas Vikram Singh, Madhukar Rai, Geeta Rai
Article
Immunology
Raquel Bartolome-Casado, Ole J. B. Landsverk, Sudhir Kumar Chauhan, Lisa Richter, Danh Phung, Victor Greiff, Louise F. Risnes, Ying Yao, Ralf S. Neumann, Sheraz Yaqub, Ole Oyen, Rune Horneland, Einar Martin Aandahl, Vemund Paulsen, Ludvig M. Sollid, Shuo-Wang Qiao, Espen S. Baekkevold, Frode L. Jahnsen
JOURNAL OF EXPERIMENTAL MEDICINE
(2019)
Article
Multidisciplinary Sciences
Xavier Tekpli, Tonje Lien, Andreas Hagen Rossevold, Daniel Nebdal, Elin Borgen, Hege Oma Ohnstad, Jon Amund Kyte, Johan Vallon-Christersson, Marie Fongaard, Eldri Undlien Due, Lisa Gregusson Svartdal, My Anh Tu Sveli, Oystein Garred, Arnoldo Frigessi, Kristine Kleivi Sahlberg, Therese Sorlie, Hege G. Russnes, Bjorn Naume, Vessela N. Kristensen, Anne-Lise Borresen-Dale, Ellen Schlichting, Torill Sauer, Jurgen Geisler, Solveig Hofvind, Tone F. Bathen, Olav Engebraten, Gry Aarum Geitvik, Anita Langerod, Rolf Karesen, Gunhild Mari Maelandsmo, Ole Christian Lingjaerde, Helle Kristine Skjerven, Daehoon Park, Britt Fritzman
NATURE COMMUNICATIONS
(2019)
Article
Medicine, Research & Experimental
J. A. Kyte, A. Rossevold, R. S. Falk, B. Naume
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Article
Medicine, Research & Experimental
J. A. Kyte, N. K. Andresen, H. G. Russnes, S. O. Fretland, R. S. Falk, O. C. Lingjaerde, B. Naume
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Article
Immunology
Raquel Bartolome-Casado, Ole J. B. Landsverk, Sudhir Kumar Chauhan, Frank Saetre, Kjersti Thorvaldsen Hagen, Sheraz Yaqub, Ole Oyen, Rune Horneland, Einar Martin Aandahl, Lars Aabakken, Espen S. Baekkevold, Frode L. Jahnsen
Summary: Studies have shown that the majority of CD4(+)T cells in the transplanted duodenum remain donor-derived resident cells after one year, with a strong cytokine-producing capability mainly as polyfunctional T(H)1 cells. This finding is important for the development of oral vaccines and therapies for gut diseases.
MUCOSAL IMMUNOLOGY
(2021)
Meeting Abstract
Oncology
J. A. Kyte, N. K. Andresen, C. Quaghebeur, B. Gilje, B. Boge, A. Gombos, A. Rossevold, R. M. R. Mathiesen, E. Borgen, R. S. Falk, L. Julsrud, H. G. Russnes, O. C. Lingjaerde, B. Naume
ANNALS OF ONCOLOGY
(2022)
Article
Immunology
Sehee Rim, Sunniva T. T. Sakkestad, Fan Zhou, Stein-Erik Gullaksen, Jorn Skavland, Sudhir K. K. Chauhan, Hans Steinsland, Kurt Hanevik
Summary: This study aimed to explore the role of cellular immunity in protection against human ETEC infection. Nine volunteers were experimentally infected with ETEC, of which six developed diarrhea. The study found that in the diarrhea group, natural killer cells increased, dendritic cells tended to rise, and mucosal-associated invariant T cells decreased. In the nondiarrhea group, these same cell populations expanded earlier, suggesting a potential role in controlling ETEC infections.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2023)
Article
Allergy
Sudhir Kumar Chauhan, Raquel Bartolome Casado, Ole J. B. Landsverk, Hanna Johannessen, Danh Phung, Hogne Roed Nilsen, Frank Saetre, Jorgen Jahnsen, Rune Horneland, Sheraz Yaqub, Einar Martin Aandahl, Knut E. A. Lundin, Espen S. Baekkevold, Frode L. Jahnsen
Summary: This study characterizes two subsets of Treg cells in the human small intestine with different phenotypes and functional capacities. Both subsets are scarce in healthy gut but increase dramatically in active celiac disease.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)